These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38361930)

  • 21. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
    Janjigian YY; Kawazoe A; Bai Y; Xu J; Lonardi S; Metges JP; Yanez P; Wyrwicz LS; Shen L; Ostapenko Y; Bilici M; Chung HC; Shitara K; Qin SK; Van Cutsem E; Tabernero J; Li K; Shih CS; Bhagia P; Rha SY;
    Lancet; 2023 Dec; 402(10418):2197-2208. PubMed ID: 37871604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in the therapeutic landscape of oesophago-gastric cancers.
    Fokter Dovnik N; Smyth EC
    Curr Opin Oncol; 2021 Jul; 33(4):362-367. PubMed ID: 33720069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
    Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
    Peng Z; Liu T; Wei J; Wang A; He Y; Yang L; Zhang X; Fan N; Luo S; Li Z; Gu K; Lu J; Xu J; Fan Q; Xu R; Zhang L; Li E; Sun Y; Yu G; Bai C; Liu Y; Zeng J; Ying J; Liang X; Xu N; Gao C; Shu Y; Ma D; Dai G; Li S; Deng T; Cui Y; Fang J; Ba Y; Shen L
    Cancer Commun (Lond); 2021 Nov; 41(11):1173-1182. PubMed ID: 34665942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
    Janjigian YY; Kawazoe A; Yañez P; Li N; Lonardi S; Kolesnik O; Barajas O; Bai Y; Shen L; Tang Y; Wyrwicz LS; Xu J; Shitara K; Qin S; Van Cutsem E; Tabernero J; Li L; Shah S; Bhagia P; Chung HC
    Nature; 2021 Dec; 600(7890):727-730. PubMed ID: 34912120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
    Emens LA; Asquith JM; Leatherman JM; Kobrin BJ; Petrik S; Laiko M; Levi J; Daphtary MM; Biedrzycki B; Wolff AC; Stearns V; Disis ML; Ye X; Piantadosi S; Fetting JH; Davidson NE; Jaffee EM
    J Clin Oncol; 2009 Dec; 27(35):5911-8. PubMed ID: 19805669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
    Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
    Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.
    Yu J; Wang Q; Wang L; Zong D; He X
    Medicine (Baltimore); 2024 Aug; 103(34):e39271. PubMed ID: 39183403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.
    Wang L; Li X; Cheng Y; Yang J; Liu S; Ma T; Luo L; Hu Y; Cai Y; Yan D
    Front Immunol; 2021; 12():784861. PubMed ID: 35069555
    [No Abstract]   [Full Text] [Related]  

  • 30. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.
    Bajetta E; Di Bartolomeo M; Carnaghi C; Buzzoni R; Mariani L; Gebbia V; Comella G; Pinotti G; Ianniello G; Schieppati G; Bochicchio AM; Maiorino L
    Br J Cancer; 1998 Apr; 77(7):1149-54. PubMed ID: 9569054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
    BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.
    Hackshaw MD; Bui CL; Ladner A; Tu N; Islam Z; Ritchey ME; Salas M
    Cancer Treat Res Commun; 2020; 24():100189. PubMed ID: 32673845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
    Shinchi Y; Ishizuka S; Komohara Y; Matsubara E; Mito R; Pan C; Yoshii D; Yonemitsu K; Fujiwara Y; Ikeda K; Tamada K; Sakagami T; Suzuki M
    Cancer Immunol Immunother; 2022 Nov; 71(11):2645-2661. PubMed ID: 35352168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
    Huang L; Wang R; Xie K; Zhang J; Tao F; Pi C; Feng Y; Gu H; Fang J
    Breast Cancer Res Treat; 2022 Jan; 191(1):51-61. PubMed ID: 34657203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer.
    Gürbüz M; Akkuş E; Sakin A; Urvay S; Demiray AG; Şahin S; Şakalar T; Erol C; Şendur MAN; Şahin AB; Çubukçu E; Güven DC; Kılıçkap S; Ergün Y; Uncu D; Turhal NS; Üskent N; Yeşil Çınkır H; Demir A; Acar R; Karadurmuş N; Türker S; Altınbaş M; Karaoğlan M; Çay Şenler F
    Tumori; 2021 Oct; 107(5):416-423. PubMed ID: 33167790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
    Qin S; Ji J; Xu RH; Wang W; Tang Y; Bi F; Li J; Wang K; Xu JM; Fan Q; Su W; Shen L
    Oncologist; 2021 Sep; 26(9):e1567-e1580. PubMed ID: 34003545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.